Episode Details
Back to Episodes
Pharmaceutical Executive Daily: September 24, 2025
Published 7 months, 3 weeks ago
Description
In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.